Medtronic PLC $MDT Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in Medtronic PLC (NYSE:MDT) by 0.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,468,260 shares of the medical technology company’s stock after purchasing an additional 192,410 shares during the period. Bank of New York Mellon Corp owned approximately 1.67% of Medtronic worth $2,044,637,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC raised its holdings in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC increased its position in shares of Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after buying an additional 381 shares in the last quarter. V Square Quantitative Management LLC raised its stake in shares of Medtronic by 5.9% during the 2nd quarter. V Square Quantitative Management LLC now owns 12,591 shares of the medical technology company’s stock worth $1,098,000 after buying an additional 701 shares during the last quarter. HB Wealth Management LLC boosted its position in shares of Medtronic by 5.4% in the 2nd quarter. HB Wealth Management LLC now owns 101,269 shares of the medical technology company’s stock worth $8,828,000 after buying an additional 5,192 shares in the last quarter. Finally, XML Financial LLC grew its stake in Medtronic by 16.6% in the 2nd quarter. XML Financial LLC now owns 15,081 shares of the medical technology company’s stock valued at $1,315,000 after acquiring an additional 2,146 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Performance

Medtronic stock opened at $100.71 on Wednesday. The stock has a fifty day moving average price of $99.52 and a 200 day moving average price of $95.48. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The firm has a market capitalization of $129.12 billion, a P/E ratio of 27.15, a PEG ratio of 2.65 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the previous year, the business earned $1.26 EPS. The firm’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is 76.55%.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Daiwa Capital Markets upped their price target on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Robert W. Baird set a $103.00 target price on Medtronic in a research note on Tuesday, December 16th. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. UBS Group boosted their price target on Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a report on Wednesday, November 19th. Finally, Truist Financial dropped their price objective on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a research report on Thursday, December 18th. Fourteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).